Literature DB >> 15820320

Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms.

Arun K Tiwari1, Smita N Deshpande, A R Rao, Triptish Bhatia, Bernard Lerer, Vishwajit L Nimgaonkar, B K Thelma.   

Abstract

Tardive dyskinesia is a severe debilitating movement disorder characterized by choreoathetotic movements developing in one-fifth of the patients with schizophrenia. In this study we have investigated the significance of CYP3A4*1B and CYP2D6*4 polymorphisms in TD susceptibility among chronic schizophrenia patients (n = 335) from north India. Tardive dyskinesia was diagnosed in approximately 29% (96/335) of these patients. No significant association of either of the two SNPs with TD (CYP3A4*1B chi2 = 0. 308, df = 1, p = 0.579; CYP2D6*4 chi2 = 0.006, df = 1, p = 0.935) was observed. However a trend towards increased severity of TD in patients heterozygous for the CYP2D6*4 mutation was observed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15820320     DOI: 10.1016/j.schres.2004.12.011

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  18 in total

Review 1.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

2.  Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: preliminary findings.

Authors:  Mariana Cherner; Chad Bousman; Ian Everall; Daniel Barron; Scott Letendre; Florin Vaida; J Hampton Atkinson; Robert Heaton; Igor Grant
Journal:  J Int Neuropsychol Soc       Date:  2010-08-23       Impact factor: 2.892

Review 3.  Medication-Induced Tardive Dyskinesia: A Review and Update.

Authors:  Elyse M Cornett; Matthew Novitch; Alan David Kaye; Vijay Kata; Adam M Kaye
Journal:  Ochsner J       Date:  2017

4.  Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: role of oxidative stress pathway genes.

Authors:  B K Thelma; Arun K Tiwari; Smita N Deshpande; Bernard Lerer; Vishwajit L Nimgaonkar
Journal:  Schizophr Res       Date:  2007-02-21       Impact factor: 4.939

Review 5.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

6.  Association study of MiRSNPs with schizophrenia, tardive dyskinesia and cognition.

Authors:  Jibin John; Triptish Bhatia; Prachi Kukshal; Puneet Chandna; Vishwajit L Nimgaonkar; Smita N Deshpande; B K Thelma
Journal:  Schizophr Res       Date:  2016-04-19       Impact factor: 4.939

Review 7.  Pharmacogenetics of antipsychotics.

Authors:  Eva J Brandl; James L Kennedy; Daniel J Müller
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

Review 8.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

9.  Relapse of tardive dyskinesia due to reduction in clozapine dose.

Authors:  Meena Shrivastava; Bhupendra Solanke; Ganesh Dakhale; Abhishek Somani; Pravir Waradkar
Journal:  Indian J Pharmacol       Date:  2009-08       Impact factor: 1.200

Review 10.  Pharmacogenomics can improve antipsychotic treatment in schizophrenia.

Authors:  Qingqing Xu; Xi Wu; Yuyu Xiong; Qinghe Xing; Lin He; Shengying Qin
Journal:  Front Med       Date:  2013-04-21       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.